TherapeuticsMD (TXMD) Q2 2024 earnings summary

Executive summary

• Transitioned to a pharmaceutical royalty company after divesting commercial operations in December 2022, now primarily collecting royalties from licensees.

• Net loss from continuing operations for Q2 2024 was $1.05M, improved from $2.41M in Q2 2023.

• License revenue for Q2 2024 was $234K, down 46.5% year-over-year, mainly due to lower sales of licensed products.

• Operating expenses declined 8.1% to $2.67M in Q2 2024, reflecting cost reductions after the business transition, partially offset by a patent impairment.

• Actively evaluating strategic alternatives, including potential acquisitions, mergers, or asset sales, with no set timetable for completion.

Financial highlights

• Net loss per share improved to $(0.09) in Q2 2024 from $(0.24) year-over-year.

• Net loss for the first six months of 2024 was $1.82M, compared to $6.02M in the prior year period.

• Cash and cash equivalents as of June 30, 2024, were $5.23M.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months due to liquidity risks and unresolved working capital adjustments.

• Exploring strategic alternatives to enhance shareholder value, but no assurance on timing or outcome.

• Additional capital may be needed to fund operations until cash flow positive; equity and debt financing options are being considered.